{"id":"NCT01444651","sponsor":"Thomas J. Wang, MD","briefTitle":"A Trial of Tadalafil and Glycemic Traits","officialTitle":"Phase 3 Randomized Trial of Tadalafil and Glycemic Traits","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-08","primaryCompletion":"2013-03","completion":"2013-03","firstPosted":"2011-10-03","resultsPosted":"2017-01-30","lastUpdate":"2017-01-30"},"enrollment":73,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Cardiovascular Disease","Insulin Resistance","Glucose Intolerance","Obesity"],"interventions":[{"type":"DRUG","name":"Tadalafil","otherNames":["Adcirca, Cialis"]},{"type":"DRUG","name":"Placebo","otherNames":["Sugar pill"]}],"arms":[{"label":"Tadalafil","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to find out if tadalafil can help overweight and obese people metabolize blood sugar more efficiently. The investigators also want to find out if 20 mg/day of tadalafil for 3 months is safe to take without causing too many side effects. The investigators are plan to enroll 100 subjects at Massachusetts General Hospital (MGH).","primaryOutcome":{"measure":"Change in Insulin Resistance From Baseline to 3 Months, as Measured by HOMA-IR","timeFrame":"Baseline and 3 months","effectByArm":[{"arm":"Tadalafil","deltaMin":3.57,"sd":2.86},{"arm":"Placebo","deltaMin":3.84,"sd":3.8}],"pValues":[{"comp":"OG000 vs OG001","p":"0.34"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":17},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["25213566"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":36},"commonTop":["Headache","Back or leg pain","Blurry vision and headache","Headache and back ache","arm pain"]}}